Featured Research

from universities, journals, and other organizations

New Avenue Of HIV Damage Found

Date:
October 10, 2002
Source:
University Of Minnesota
Summary:
Researchers at the University of Minnesota have discovered a new process by which HIV damages the immune system. They demonstrated that the portion of lymph nodes called the T cell zone is significantly damaged by chronic inflammation, which causes fibrosis. This is important because the T cell zone is where a significant portion of the human immune response occurs. The finding of accumulation of scar tissue in this portion of the lymph node may explain why aggressive anti-retroviral therapy (ART) does not improve the immune system in some people with HIV-1 infection.

MINNEAPOLIS / ST. PAUL -- Researchers at the University of Minnesota have discovered a new process by which HIV damages the immune system. They demonstrated that the portion of lymph nodes called the T cell zone is significantly damaged by chronic inflammation, which causes fibrosis. This is important because the T cell zone is where a significant portion of the human immune response occurs. The finding of accumulation of scar tissue in this portion of the lymph node may explain why aggressive anti-retroviral therapy (ART) does not improve the immune system in some people with HIV-1 infection. The study findings will be published in the Oct. 16, 2002, issue of the Journal of Clinical Investigation. The paper can be found at http://www.jci.org.

Related Articles


"HIV infection ultimately depletes the body of CD4 T cells, making it impossible to mount an immune response," said Timothy W. Schacker, M.D., associate professor of medicine and author of the study. "For the first time, we show that one mechanism of this depletion is damage to the structure that these cells need to maintain a normal-sized population and to mount an immune response to other infections. In essence, the T cell home is destroyed."

Researchers enrolled 11 individuals at various stages of HIV/AIDS infection. Their goal was to understand the specific changes that happen in the population of cells most directly affected by HIV--the CD4 T cells. These cells are responsible for coordinating the immune response and are the primary target for HIV infection and replication. Researchers biopsied and examined the lymph node tissue before and during treatment for HIV. They have developed sensitive methods to precisely measure both the size of the CD4 population in lymphatic tissue and the amount of scar tissue accumulated in the T cell zone.

Researchers noted two significant findings. First, the size of the CD4 T cell population measured in peripheral blood (commonly done to stage the disease and determine the effects of treatment) does not accurately reflect the size of the population in lymph tissues. "You could have a reasonable peripheral count and a very poor count in lymph tissues," said Schacker.

Second, the amount of fibrosis and scar tissue in the T cell zone was significantly related to the size of the CD4 population in that space (i.e. the more scar tissue, the fewer cells) and the recovery of the CD4 population with therapy. The researchers suggest the process of destruction is analogous to what is seen in chronic active hepatitis.

"We knew that T cells are destroyed by direct viral replication," said Schacker, "but we now know that the population is unable to recover to a normal size because the environmental niche used to support the cells is destroyed. New CD4 T cells are unable to get into the space they need to be in to function, and there is no space for the cells to divide."

One implication of this discovery is that through testing of the lymph nodes (similar to what is done to stage cancer), physicians might accurately stage the disease and predict the response to standard therapies.

"This is essentially a new concept in how HIV infection causes damage to the human immune system," said Schacker. "Our observation may explain why up to 25 percent of people placed on HIV therapy may have good viral suppression but still have no significant increase in T cell count.

"Currently, most treatment strategies for HIV/AIDS focus on stopping the virus from replicating itself in the body, which is essential to begin the process of immune reconstitution, but it does not happen for everyone. These findings suggest that therapies targeting the damage from inflammation and accumulation of scar tissue might enhance current antiviral therapy."

The work was performed at the university's General Clinical Research Center, part of the Academic Health Center. The work was supported by the National Institutes of Health.

The Academic Health Center is home to the University of Minnesota's seven health professional schools and colleges as well as several health-related centers and institute. Founded in 1851, the University is one of the oldest and largest land grant institutions in the country. The AHC mission is to prepare the new health professionals who improve the health of communities, discover and deliver new treatments and cures and strengthen the economy.


Story Source:

The above story is based on materials provided by University Of Minnesota. Note: Materials may be edited for content and length.


Cite This Page:

University Of Minnesota. "New Avenue Of HIV Damage Found." ScienceDaily. ScienceDaily, 10 October 2002. <www.sciencedaily.com/releases/2002/10/021010065809.htm>.
University Of Minnesota. (2002, October 10). New Avenue Of HIV Damage Found. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2002/10/021010065809.htm
University Of Minnesota. "New Avenue Of HIV Damage Found." ScienceDaily. www.sciencedaily.com/releases/2002/10/021010065809.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Fauci Says Ebola Risk in US "essentially Zero"

Fauci Says Ebola Risk in US "essentially Zero"

AP (Oct. 30, 2014) NIAID Director Anthony Fauci said the risk of Ebola becoming an epidemic in the U.S. is essentially zero Thursday at the Washington Ideas Forum. He also said an Ebola vaccine will be tested in West Africa in the next few months. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Nurse Defies Ebola Quarantine With Bike Ride

Nurse Defies Ebola Quarantine With Bike Ride

AP (Oct. 30, 2014) A nurse who vowed to defy Maine's voluntary quarantine for health care workers who treated Ebola patients followed through on her promise Thursday, leaving her home for an hour-long bike ride. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Pot-Infused Edibles Raise Concerns in Colorado

Pot-Infused Edibles Raise Concerns in Colorado

AFP (Oct. 30, 2014) Colorado may have legalized marijuana for recreational use, but the debate around the decision still continues, with a recent - failed - attempt to ban cannabis-infused edibles. Duration: 01:53 Video provided by AFP
Powered by NewsLook.com
British Navy Ship Arrives in Sierra Leone With Ebola Aid

British Navy Ship Arrives in Sierra Leone With Ebola Aid

AFP (Oct. 30, 2014) The British ship RFA ARGUS arrived in Sierra Leone to deliver supplies and equipment to help the fight against Ebola. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins